Clinical trials: Disease, Hodgkin
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
This is a multicenter, open-label, Phase 2 study to assess the efficacy and safety of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) with EZH2 gene mutation.
- Trial name
- NCT03456726
- Testing
- Tazemetostat
- Where
- 28 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Eisai Co., Ltd.
Non-Hodgkin's Lymphoma
Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease.
- Trial name
- NCT00057343
- Testing
- Zevalin (ibritumomab tiuxetan), Rituxan (rituximab)
- Where
- 67 sites in United States
- Volunteers
- 400 people
- Sponsor
- Biogen
Lymphoma,Non-Hodgkin
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have…
- Trial name
- CHRONOS-3 (NCT02367040)
- Testing
- Copanlisib (Aliqopa, BAY80-6946), Rituximab
- Where
- 187 sites in United States, Argentina and 35 more
- Volunteers
- 458 people
- Sponsor
- Bayer
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell
A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
This study is evaluating whether an experimental treatment called GLPG5101 helps to treat non-Hodgkin lymphoma (NHL) and if it is safe to use.
- Trial name
- Atalanta-1 (NCT06561425)
- Testing
- GLPG5101
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 130 people
- Sponsor
- Lakefront Biotherapeutics NV
Non-Hodgkin Lymphoma
Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy
This is a single arm, open-label, early phase Ⅰ study, to determine the safety and efficacy of CD19-TriCAR-T and CD19-TriCAR-SILK cell therapy in Non-Hodgkin lymphoma treatment.
- Trial name
- NCT03790891
- Testing
- CD19-TriCAR-T/SILK
- Where
- 3 sites in China
- Volunteers
- 12 people
- Sponsor
- Timmune Biotech Inc.
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT02851589
- Testing
- PCAR-019 (anti-CD19 CAR-T cells)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Diffuse Large B-Cell Lymphoma
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
[Phase I part] To investigate the safety, tolerability, and pharmacokinetics of MT-2111 monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT05658562
- Testing
- MT-2111
- Where
- 23 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Tanabe Pharma Corporation
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: can a dose of JNJ-90009530 be determined that is safe and well…
- Trial name
- NCT05784441
- Testing
- JNJ-90009530
- Where
- 15 sites in United States, Australia and 2 more
- Volunteers
- 21 people
- Sponsor
- Janssen Research & Development, LLC
Relapsed or Refractory Hodgkin Lymphoma, Relapsed or Refractory Anaplastic Large-cell Lymphoma
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
The purpose of this study is to assess the safety and pharmacokinetics, and determine the pediatric maximum tolerated dose and/or or recommended phase 2 dose of brentuximab vedotin.
- Trial name
- NCT01492088
- Testing
- Brentuximab vedotin
- Where
- 18 sites in United States, France and 6 more
- Volunteers
- 36 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
This is an open-label, multicenter, prospective pilot study of CDX-301 with or without plerixafor as a stem cell mobilizer for allogeneic transplantation (stem cells that come from another person).
- Conditions
- For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling, For Recipients, Acute Myelogenous Leukemia (AML)
- Trial name
- NCT02200380
- Testing
- CDX-301, CDX-301 and plerixafor
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
Lymphoma, Large-Cell, Diffuse
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
The purpose of this trial is to determine the effect of ofatumumab in patients with Diffused Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant
- Trial name
- NCT00622388
- Testing
- Ofatumumab
- Where
- United Kingdom
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03893682
- Testing
- CG-806
- Where
- 30 sites in United States
- Volunteers
- 36 people
- Sponsor
- Aptose Biosciences Inc.
Classic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
This is a phase 2 multi-cohort, un-controlled, non-randomized, open-label, multi-center study that assessed the antitumor activity and safety of non-alpha interleukin (IL-2) SAR444245 with or without other anticancer therapies in…
- Trial name
- NCT05179603
- Testing
- THOR-707, Pembrolizumab
- Where
- 8 sites in Argentina, Chile and 1 more
- Volunteers
- 14 people
- Sponsor
- Sanofi
Wrinkle Severity Rating Scale(WSRS) Grade 3 (Moderate) or 4 (Severe) of Nasolabial Folds
Clinical Trial of YYD701-2 for Treatment of Nasolabial Folds
A multicenter, active-controlled, randomized, evaluator and subject blinded, split-face, comparative, non-inferiority, Medical device Clinical trial.
- Trial name
- NCT03170050
- Testing
- YYD701-2, Restylane Perlane Lidocaine
- Where
- 2 sites in South Korea
- Volunteers
- 107 people
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating…
- Trial name
- NCT00083213
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Moderate Aortic Valve Stenosis
Evolut™ EXPAND TAVR II Pivotal Trial
Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.
- Trial name
- NCT05149755
- Testing
- Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)
- Where
- 94 sites in United States, Australia and 14 more
- Volunteers
- 650 people
- Sponsor
- Medtronic Cardiovascular
BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include
A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women
A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and…
- Conditions
- BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency, Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe
- Trial name
- NCT02210689
- Testing
- clindamycin phosphate vaginal cream 2%
- Where
- 18 sites in United States, Dominican Republic and 1 more
- Volunteers
- 604 people
- Sponsor
- Actavis Inc.
Anemia
A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B
This study will examine the efficacy, safety and effect on hemoglobin levels, of once weekly subcutaneous injections of epoetin beta (30,000 IU) in anemic participants with non-Hodgkin's lymphoma, chronic lymphocytic leukemia or…
- Trial name
- NCT02608060
- Testing
- Epoetin Beta
- Where
- 2 sites in Venezuela
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Non Hodgkin's Lymphoma
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma
The main treatments for non-Hodgkin's lymphoma are surgery, radiotherapy, chemotherapy, and bone marrow transplantation. Neutropenia is the most common and serious complication of most chemotherapy.
- Trial name
- NCT04497688
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 104 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Lymphoma, T-Cell, Cutaneous
CPG 7909 in Patients With Cutaneous T-Cell Lymphoma
To assess the effect of CPG 7909 Injection on Cutaneous T-cell lymphoma and the safety of CPG 7909 Injection in patients with this cancer.
- Trial name
- NCT00043420
- Testing
- PF-3512676
- Volunteers
- 42 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.